Background {#Sec1}
==========

Childbirth is usually the most challenging and painful experience of a mother's life \[[@CR1]\]. Fear of childbirth has increased the cesarean delivery rate. Due to the fact that natural vaginal delivery has many advantages compared with cesarean section and promotion of natural vaginal delivery is considered important by the health care systems, labor analgesia has become a key concern for both puerperal and clinical anesthesiologists \[[@CR2]\].

At present, labor analgesia methods include non- pharmacological analgesia and pharmacological analgesia. Non-pharmacological analgesia mainly includes acupuncture, massage, yoga and hydrotherapy and the analgesic effect of which is poor although there is no maternal and fetal injury \[[@CR3]\]. For pharmacological analgesia, there are intramuscular analgesics, intravenous analgesics, and spinal analgesia. Among them, intraspinal labor analgesia is the best method for clinical application of analgesia, including continuous epidural analgesia (CEA), combined spinal-epidural anesthesia (CSEA) and continuous spinal anesthesia \[[@CR4], [@CR5]\]. Epidural analgesia is considered as a widely practiced analgesic technique in clinic worldwide \[[@CR6]\]. An ideal labor analgesia method should exhibit good analgesic effect, increase subject satisfaction and comfort, and reduce the incidence of adverse pregnancy outcomes and adverse drug reactions without affecting the progress of labor \[[@CR7]\].

In recent years, with the development of anesthesia technology, combined spinal-epidural anesthesia has increasingly used in labor analgesia because it combines the advantages of epidural anesthesia and spinal anesthesia, including rapid onset, significant analgesic effect, lower drug dosage and fewer side effects \[[@CR8], [@CR9]\]. However, there are few reports on the specific anesthesia methods and medication regimens of combined spinal-epidural anesthesia, which is not conducive to guiding clinical work. Here, we compared the clinical effects of combined spinal-epidural anesthesia and continuous epidural anesthesia, to provide guidance for clinical work.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

In this retrospective, single-center case-control analysis, a total of 360 cases of voluntary acceptance of painless childbirth pregnant from October 2017 to August 2018 in the Beijing Obstetrics and Gynecology Hospital were selected in this study retrospectively. The inclusion criteria were: (1) primiparous women; (2) at first full-term pregnancy, singleton pregnancies; and (3) cephalic, and had no spinal deformity. Exclusion criteria were: (1) pregnant women who had contraindication to epidural anesthesia; (2) pregnant women who had signs of fetal distress; (3) pregant women with contraindications for vaginal delivery. The subjects were divided into observation group and control group according to anesthetic method (*n* = 180 in each group, control: case were 1:1). For the observation group, combined spinal-epidural anesthesia (CSEA group) was used. Cases in control group received continuous epidural anesthesia (CEA group). Ropivacaine combined with sufentanil were used in all subjects. All subjects were American Society of Anesthesiologists (ASA) physical status class I or II. One hundred forty-two subjects in CSEA group and 133 subjects in CEA group were class I and 18 subjects in CSEA group and 27 subjects in CEA group were class II.

Anesthetic method {#Sec4}
-----------------

After entering the clinical delivery, the routine monitoring was established for all women, including blood pressure (BP), heart rate (HR), pulse oximetry (SpO2) and electrocardiography (ECG). Oxygen therapy by nasal catheter venous access and fetal heart monitoring was given. In terms of labor analgesia, the impact on the patient's circulation and other aspects is very small since the dosage of CSEA injected into the subarachnoid space is only 1/5--1/10 of normal CSEA anesthesia. In addition, CEA and CSEA were performed in patients with normal coagulation function. Therefore, there is no obvious tendency in the selection of indications. Both CEA and CSEA were routinely used in our department and the method was chosen according to the anesthesiologist's personal anesthesia operation habits.

For CEA group, pregnant women were placed in the left lateral position. After successful epidural puncture at L2--3 or L3--4 interspace, 3 mL of 0.5% ropivacaine (Naropin; AstraZeneca Co., Ltd.; 10 ml/100 mg; Registration number: H20140763) were slowly injected. If no occurrence of adverse reactions were observed 10 min later, pre-configured 10 mL of analgesic pump solution were given from the epidural space and epidural analgesia analgesia pump (PCEA) was then connected. The formula of analgesic pump solution was: 10 ml of l% ropivacaine combined with 0.3--0.4 μg/ml sufentanil (Eurocept BV Trapgans 51,244 RL Ankeveen, The Netherlands; 75 μg/1 ml; Batch number: 170553) diluted to 100 ml with 0.9% sterile saline. The analgesic pump parameters were set as follows: continuous background infusion of 5 ml/h, single additional dose (PCA) of 7 ml/time, interval lockout time of 15 min and total amount of 100 ml.

For pregnant women in CSEA group, after successful epidural puncture at L2--3 or L3--4 interspace, a 25-G lumbar puncture needle was inserted through the epidural needle (Xinxiang Camel Medical Devices Co., Ltd.; Batch number: 1310015). After the cerebrospinal fluid was seen 2--3 mg of 0.1% ropivacaine (diluted to 2--3 ml with sterile saline) was then injected into the subarachnoid space. After 3--4 cm of epidural catheter was set to the head side, subjects in both groups were placed in the supine position. Ten minutes later, epidural analgesia analgesia pump (PCEA) was connected after no occurrence of adverse reactions were observed. The formula of analgesic pump solution and analgesic pump parameters were the same as CEA group.

For both groups, the heart rate, blood pressure and fetal heart rate of the pregnant women were closely monitored during the process of analgesia and childbirth. After the uterine cervix was opened, the pump fluid infusion was stopped, and the epidural catheter was pulled out 2 h after delivery.

Observation indexes {#Sec5}
-------------------

The onset time of analgesia, T1, T2, T3, total labor time and doses of ropivacaine and sufentanil in two groups were recorded. Pain was assessed by visual analog scale (VAS) \[[@CR10]\] scores at four time points: (1) T~0~, stage before analgesia; (2) T~1~, from the beginning of uterine contractions to cervical dilatation of 10 cm; (3) T~2,~ from cervical dilatation of 10 cm to the delivery of the baby; (4) T~3~, From the delivery of the baby to the delivery of the placenta. The T~0~, T~1~, T~2~ and T~3~ in this study were defined according to the guidelines from the National Institute for Health and Clinical Excellence \[[@CR11]\].

The Apgar scores were assessed at 1, 5, and 10 min after birth \[[@CR12]\]. Apgar scores of 8--10 points were considered normal for newborns; 4--7 points indicated mild asphyxia; and 0--3 points suggested severe asphyxia.

Maternal satisfaction evaluation were performed based on subjects' feelings during different labor periods on labor analgesia (80--100: very satisfactory; 60--80: general satisfactory; below 60: unsatisfactory).

Finally, the adverse pregnancy outcomes and adverse drug reactions were observed.

Statistical analysis {#Sec6}
--------------------

All statistical analyses were conducted with SPSS software, version 18.0 (SPSS Inc., Chicago, USA). PP plot (probability-probability plot) indicates the normal distribution of data. Values are presented as mean ± standard deviation (SD) or number (percentage) at appropriate. Quantitative variables (VAS scores, labor time, apgar scores and doses of ropivacaine and sufentanil) were compared by *Student's t test* and χ2 test was used for categorical variables (adverse pregnancy outcomes and adverse drug reactions). Repeated-measures ANOVA were used for the comparison of different time points within the group. All reported *P* values are two-sided, and *P* value of less than 0.05 was considered statistically significant.

Results {#Sec7}
=======

There were no significant differences with regard to age, height, weight, BMI and duration of pregnancy between CSEA group and CEA group (*P* \> 0.05) (Table [1](#Tab1){ref-type="table"}). Table 1Clinical characteristics of subjects (mean ± SD)CEA (*n* = 180)CSEA (*n* = 180)*P* valueAge, years26.8 ± 4.227.1 ± 3.90.483Height, cm160.4 ± 4.3161.3 ± 4.60.056Weight, kg65.4 ± 16.266.3 ± 15.60.592BMI, kg/m^2^22.3 ± 3.422.2 ± 3.10.771Duration of pregnancy, weeks38.5 ± 1.338.3 ± 1.40.161*BMI* Body Mass Index. *P* value of comparison between CSEA and CEA groups

VAS scores in two groups {#Sec8}
------------------------

There was no significant differenceregarding VAS scores at T~0~ between two groups (*P* \> 0.05). In two groups, VAS scores at T~1~, T~2~ and T~3~ were significantly lowercompared with T~0~ in the same group (*P* \< 0.01). VAS scores at T~1~, T~2~ and T~3~ in CSEA group were significantly lower compared with those in CEA group at the same time (*P* \< 0.01) (Table [2](#Tab2){ref-type="table"}). Table 2Comparison of pain VAS scores at different times in two groups (mean ± SD)CEA (*n* = 180)CSEA (*n* = 180)T~0~ (min)8.32 ± 1.378.36 ± 1.35T~1~(min)3.35 ± 0.64^\*^3.02 ± 0.67^\*\#^T~2~ (min)4.22 ± 0.87^\*^3.84 ± 0.83^\*\#^T~3~ (min)6.84 ± 1.26^\*^5.31 ± 1.12^\*\#\*^*P* \< 0.01, vs T~0~; ^\#^*P* \< 0.01, vs CEA group

Labor time in two groups {#Sec9}
------------------------

The onset time, T~1~ and total labor time in CSEA group were significantly shorter than those in CEA group (*P* \< 0.01). However, there was no significant difference regarding labor time at T~2~ and T~3~ between two groups (*P* \> 0.05) (Table [3](#Tab3){ref-type="table"}). Table 3Comparison of labor time in two groups (mean ± SD)CEA (*n* = 180)CSEA (*n* = 180)*P* valueOnset time (min)6.32 ± 3.453.21 ± 1.42\< 0.001T~1~(min)524.33 ± 126.46468.32 ± 114.10\< 0.001T~2~(min)48.24 ± 10.3446.09 ± 11.220.060T~3~(min)7.38 ± 0.767.24 ± 0.830.096Total labor time (min)578.29 ± 132.08512.67 ± 124.38\< 0.001

Apgar scores in two groups {#Sec10}
--------------------------

There were no significant differences in Apgar scores at 1, 5, and 10 min after birth between the two groups (*P* \> 0.05) (Table [4](#Tab4){ref-type="table"}). Table 4The Apgar scores at 1, 5, and 10 min after birth in two groups (mean ± SD)CEA (*n* = 180)CSEA (*n* = 180)*P* value1 min after birth8.47 ± 0.348.41 ± 0.350.0995 min after birth8.85 ± 0.418.83 ± 0.420.64710 min after birth9.52 ± 0.389.48 ± 0.330.278

Adverse pregnancy outcomes in two groups {#Sec11}
----------------------------------------

There were no significant differences in adverse pregnancy outcomes after labor analgesia between the two groups (*P* \> 0.05) (Table [5](#Tab5){ref-type="table"}), including obstetric apparatus, cesarean, 24 h postpartum hemorrhage and episiotomy. Table 5Comparison of adverse pregnancy outcomes in two groups (mean ± SD)CEA (*n* = 180)CSEA (*n* = 180)*P* valueObstetric apparatus, n (%)7 (3.89)8 (4.45)0.792Cesarean, n (%)18 (10.00)22 (12.22)0.49924 h postpartum hemorrhage, n (%)6 (3.33)5 (2.78)0.759Episiotomy, n (%)22 (12.22)16 (8.89)0.303Total adverse pregnancy outcomes, n (%)44 (24.44)41 (22.78)0.709

Doses of drugs and adverse drug reactions in two groups {#Sec12}
-------------------------------------------------------

Doses of ropivacaine and sufentanil in CSEA group were significantly lower than that in CEA group (*P* \< 0.01) (Table [6](#Tab6){ref-type="table"}). There were no significant differences in the rates of uroschesis and respiratory depression between two groups (*P* \> 0.05). However, the rates of nausea, vomiting, pruritus and total adverse drug reactions in CSEA group were significantly lower than these in CEA group (*P* \< 0.01). Besides, subject satisfaction in CSEA group were significantly higher than that in CEA group (*P* \< 0.01) (Table [7](#Tab7){ref-type="table"}). Table 6Doses of Ropivacaine and Sufentanil in each group. (mean ± SD)CEA (*n* = 180)CSEA (*n* = 180)*P* valueRopivacaine39.88 ± 4.5238.42 ± 3.16\< 0.001Sufentanil19.98 ± 6.6616.01 ± 5.26\< 0.001 Table 7Comparison of adverse drug reactions in two groupsCEA (*n* = 180)CSEA (*n* = 180)*P* valueNausea and vomiting, n (%)20 (11.11)8 (4.44)0.018Pruritus, n (%)12 (6.67)4 (2.22)0.041Uroschesis, n (%)8 (4.44)4 (2.22)0.240Respiratory depression, n (%)4 (2.22)2 (1.11)0.410Total adverse drug reactions, n (%)44 (24.44)18 (10.00)\< 0.001Subject satisfaction, n (%)120 (66.67)150 (83.33)\< 0.001

Discussion {#Sec13}
==========

Under the different combinations of ropivacaine and sufentanil, the observation and analysis of the two anesthesia methods in this study showed that CSEA was superior to CEA in analgesic effect and maternal satisfaction.

CSEA refers to a method of injecting a small amount of anesthetic drug into the subarachnoid space after successful epidural puncture \[[@CR13]\]. Currently, the combination of local anesthetic and opioid is the common compatibility program for CSEA, including bupivacaine, ropivacaine, fentanyl and sufentanil \[[@CR14], [@CR15]\]. Ropivacaine (1-propyl-2′, 6′-pipecoloxylidide, chemical structure) is an amino acid local anesthetic and was recently introduced for labor analgesia, since it has less cardiac toxicity and provide more differential block between sensory and motor \[[@CR7], [@CR16]\]. For opioids, the analgesic effect of sufentanil is 3 to 5 times more potent than fentanyl due to the strong affinity for opioid receptors \[[@CR17], [@CR18]\].

Clinically, ropivacaine combined with low-dose sufentanil has been widely used in labor analgesia \[[@CR19]\]. The combination of the two drugs allows use of lower doses of both drugs, thus decreasing the rate and severity of adverse effects \[[@CR20]\]. However, previous studies \[[@CR21], [@CR22]\] have shown that ropivacaine combined with sufentanil injected into the subarachnoid space after the spinal anesthesia pierced the dura mater resulted in a higher pruritus rates than ropivacaine alone. In this study, ropivacaine combined with sufentanil were used for CEA group. While for CSEA group, ropivacaine were used alone before epidural catheter were placed and ropivacaine combined with sufentanil were used thereafter. As a result, better analgesic effect was achieved in CSEA group compared with CEA group according to the VAS scores. Besides, the overall incidence of adverse drug reactions in CSEA group was lower than CEA group, including the lower nausea and vomiting rates and pruritus rates. The reduced dose of sufentanil were responsible for this result since complications of anesthetics were dose-dependent \[[@CR18], [@CR23]\]. Additionally, delaying sufentanil injection may exert the maximum effect of ropivacaine, which has long analgesic duration, less adverse drug reactions and differential block between sensory and motor \[[@CR24]\].

In this study, CSEA group has a relative shorter onset time compared with CEA group, which is inconsistent with a previous study \[[@CR25]\], showing that there were no differences between groups for onset time and analgesia evaluation. We assume that this possibly due to the different doses of ropivacaine and sufentanil in both studies. We found no statistically significant differences with regard to the Apgar scores of the newborns at 1, 5 and 10 min and adverse pregnancy outcomes between the two groups suggesting that CSEA could achieve the same newborn conditions as CEA with lower doses of ropivacaine and sufentanil. Maternal satisfaction were improved due to the fewer adverse drug reactions associated with intrathecal sufentanil that can be disconcerting for subjects.

The limitation of this study was that pregnant women with contraindication to epidural anesthesia were not suitable for this method. Therefore, more studies should be carried out in the future to further improve the labor analgesia method.

Conclusion {#Sec14}
==========

CSEA group in this study achieved better analgesic effect, lower onset time and fewer adverse drug reactions compared with CEA group. Thus, CSEA method with our block method and doses may provide some reference for clinical labor analgesia.
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